We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche's Tecentriq Combo Study Meets Co-Primary Endpoint
Read MoreHide Full Article
Roche Holding AG’s (RHHBY - Free Report) subsidiary Genentech announced that a phase III study, evaluating a combination of its PD-L1 inhibitor Tecentriq (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel for first line treatment of advanced lung cancer met its co-primary endpoint of overall survival (OS).
The IMpower150 study showed that the patients with advanced non-squamous non-small cell lung cancer (NSCLC) who were treated with the combination treatment lived longer compared with Avastin plus carboplatin and paclitaxel.
The company plans to submit these additional data to global health authorities as well as to the FDA and the European Medicines Agency (EMA) soon.
Over a year, shares of Roche have declined 12.3% against the industry’s growth of 2.8%.
In December 2017, the company had announced interim results from the IMpower 150 study. The IMpower150 study showed that Tecentriq and Avastin plus chemotherapy reduced the risk of disease worsening or death by 38% compared with those who were treated with Avastin plus chemotherapy. In November 2017, Roche mentioned that the III IMpower150 study met its co-primary endpoint of progression-free survival.
Tecentriq is approved for the treatment of second-line metastatic NSCLC. Label expansion in the first line setting should boost the drug’s sales further. Tecentriq is also approved for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin chemotherapy. The drug recorded sales of CHF457 million in 2017.
We remind investors that Merck’s (MRK - Free Report) PD-L1 inhibitor Keytruda is approved by the FDA both as monotherapy and in combination with Lilly’s (LLY - Free Report) Alimta and carboplatin for the first line treatment of patients with metastatic nonsquamous NSCLC.
Regeneron’s earnings per share estimates have moved up from $18.65 to $18.68 for 2018 in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters, with an average beat of 9.15%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions. New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Roche's Tecentriq Combo Study Meets Co-Primary Endpoint
Roche Holding AG’s (RHHBY - Free Report) subsidiary Genentech announced that a phase III study, evaluating a combination of its PD-L1 inhibitor Tecentriq (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel for first line treatment of advanced lung cancer met its co-primary endpoint of overall survival (OS).
The IMpower150 study showed that the patients with advanced non-squamous non-small cell lung cancer (NSCLC) who were treated with the combination treatment lived longer compared with Avastin plus carboplatin and paclitaxel.
The company plans to submit these additional data to global health authorities as well as to the FDA and the European Medicines Agency (EMA) soon.
Over a year, shares of Roche have declined 12.3% against the industry’s growth of 2.8%.
In December 2017, the company had announced interim results from the IMpower 150 study. The IMpower150 study showed that Tecentriq and Avastin plus chemotherapy reduced the risk of disease worsening or death by 38% compared with those who were treated with Avastin plus chemotherapy. In November 2017, Roche mentioned that the III IMpower150 study met its co-primary endpoint of progression-free survival.
Tecentriq is approved for the treatment of second-line metastatic NSCLC. Label expansion in the first line setting should boost the drug’s sales further. Tecentriq is also approved for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin chemotherapy. The drug recorded sales of CHF457 million in 2017.
We remind investors that Merck’s (MRK - Free Report) PD-L1 inhibitor Keytruda is approved by the FDA both as monotherapy and in combination with Lilly’s (LLY - Free Report) Alimta and carboplatin for the first line treatment of patients with metastatic nonsquamous NSCLC.
Roche Holding AG Price
Roche Holding AG Price | Roche Holding AG Quote
Zacks Rank & Other Stock to Consider
Roche carries a Zacks Rank #2 (Buy).
Another top-ranked stock from the same space is Regeneron Pharmaceuticals (REGN - Free Report) ,sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings per share estimates have moved up from $18.65 to $18.68 for 2018 in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters, with an average beat of 9.15%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions. New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>